Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
2020 · Annals of Oncology · 454 citations
https://doi.org/10.1016/j.annonc.2020.04.010
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
41
Papers
2.0K
Citations
12
h-index
12
i10-index
S. Krishnaswami is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Rheumatoid Arthritis Research and Therapies & Chronic Lymphocytic Leukemia Research & Autoimmune and Inflammatory Disorders Research. The author has an h-index of 12, co-authored 35 publications.
https://doi.org/10.1016/j.annonc.2020.04.010
https://doi.org/10.1186/2192-5372-2-15
Click to start Chat